Altre lingue Portage Biotech Inc.

Azioni

PRTG

VGG7185A1286

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
0,271 ^USD	+12,92%		-40,44%	-85,11%

15/04	Portage Biotech annuncia l'intenzione di ampliare la valutazione delle alternative strategiche	CI
12/04	Portage Biotech annuncia l'intenzione di ampliare la valutazione delle alternative strategiche	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused	15/04
Portage biotech announces plans to expand its evaluation of strategic alternatives	15/04
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	15/04
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives	12/04
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	12/04
Portage biotech completes monetization of intensity therapeutics shares	27/03
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03
Portage Biotech : Corporate Presentation - March 2024	07/03
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update	28/02
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	28/02
Portage Biotech to Pause Drug Development in PORT-2 iNKT Program, to Cut Workforce	04/01
Portage Biotech to Evaluate Range of Strategic Options	04/01
Portage Biotech Reports Business and Strategic Update	04/01
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	28/11
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update	28/11
Portage biotech presents updates on its inkt and adenosine programs at the society for immunotherapy of cancer's 38th annual meeting	07/11
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	06/11
Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting	06/11
Portage Biotech Inc. announced that it has received $5.3 million in funding	03/10/23
Portage biotech announces $6.0 million registered direct offering	02/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Portage Biotech Inc.

Azioni

PRTG

VGG7185A1286

Altre lingue

Filtri